Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Delic Holdings Corp (DELCF) Message Board

Slow-Release DMT Infusions May Help Develop New Th

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 135
(Total Views: 204)
Posted On: 10/11/2022 5:16:16 PM
Avatar
Posted By: NetworkNewsWire
Slow-Release DMT Infusions May Help Develop New Therapy for Stroke Patients

A stroke is a form of brain injury caused by blood supply to the brain being interrupted. This medical emergency requires prompt treatment; responding too late increases the likelihood of brain damage.

Figures show that strokes are the third leading cause of death and disability around the globe, with billions in funds being allocated for long-term healthcare services, support and rehabilitation for stroke survivors. Long-term rehabilitation is usually exhaustive and lengthy, highlighting the need for a new treatment approach, especially since traditional stroke treatments are not 100% effective.

This may be realized sooner than we thought. Algernon Pharmaceuticals announced last month that it plans to conduct a phase I study looking into the use of DMT infusions for stroke.

A consultant of the company, Dr. David Nutt, stated that Algernon’s approach with DMT strengthened the natural recovery of the brain by improving neuroplasticity, which in turn facilitated the development of new neural networks. Nutt, who is also a neuropsychopharmacology professor at Imperial College London, added that this new approach was different from anything that had been tried previously.

DMT, or N,N-Dimethyltryptamine, is a hallucinogenic drug known to produce effects similar to psilocybin and LSD. This strong psychedelic is produced in a range of animal and plant species, in addition to being found in minute quantities in the human body.

However, unlike other psychedelics, DMT delivers a visually intense and almost instant trip that lasts anywhere from 30 to 45 minutes. Prior studies have shown that this psychedelic compound may provide unique therapeutic benefits as a treatment for stroke.

Algernon CEO Christopher Moreau believes that this compound represents a new way to promote recovery and healing after a patient experiences an ischemic stroke, which is a common type of stroke. The company has been conducting research on DMT’s viability as a stroke treatment for more than a year, with its earlier findings showing that the compound stimulated growth of neuron cells by 40%.

Moreau revealed that the company’s upcoming trial would focus on studying the effects of administering small doses of DMT to human participants. Algernon’s phase I trial is set to kick off in the last quarter of this year in the Netherlands. It will involve no more than 60 volunteers and will test the safety, tolerability and pharmacokinetics of DMT.

This trial is unique because the psychedelic compound will be administered to participants as slow-release IV infusions, which allows it to enter the bloodstream immediately and circulate in the body.

Currently, a number of jurisdictions allow ketamine infusions, and companies such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) have several centers that are operational in this regard; the centers also conduct development programs involving other psychedelic compounds with known medicinal potential.

NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at https://ibn.fm/DELCF

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer




(0)
(0)




Delic Holdings Corp (DELCF) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us